Faron Pharmaceuticals Oy
FPHAF
Other OTC3.30
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Markku Tapani Jalkanen
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Joukahaisenkatu 6 B Turku Finland 20520
- IPO Date
- Apr 28, 2020
- Website
- faron.com
- Similar Companies
- Business
- Faron Pharmaceuticals Oy is a Finland-based global clinical-stage biopharmaceutical company specializing in the discovery and development of innovative immunotherapies primarily for cancer, acute organ traumas, vascular damage, and blood count abnormalities. Founded in 2003 and headquartered in Turku, Finland, Faron develops novel therapeutic candidates including bexmarilimab, a first-in-class, humanized monoclonal antibody targeting the Clever-1 receptor to reprogram myeloid cell function and remove immunosuppression in hematological cancers and solid tumors, currently in Phase I/II clinical trials. Its pipeline also features Traumakine, an intravenous interferon beta-1a therapy aimed at preventing cytokine release syndrome and acute respiratory distress syndrome, and Haematokine, designed to stimulate bone marrow stem cell expansion for chemotherapy-induced neutropenia and other blood disorders. Faron engages in strategic partnerships such as manufacturing collaborations with AGC Biologics and targets broad oncology and organ damage markets through novel immune modulation mechanisms. Recent major developments include the advancement of bexmarilimab to a registrational trial phase with FDA alignment, completion of key Phase 2 milestones, receipt of regulatory approvals for new share subscriptions in 2025, and the appointment of Jurriaan Dekkers as Chief Financial Officer in December 2025 to support growth and commercialization efforts. The company continually explores new therapeutic approaches and combination treatments to extend immunotherapy benefits more widely, aiming to address unmet medical needs globally. This comprehensive focus on macrophage-targeting immunotherapies and immune environment modulation establishes Faron as a pioneering entity in clinical-stage immuno-oncology and acute organ trauma treatment development.
Faron Pharmaceuticals Oy (OTC:FPHAF) & Hyperion DeFi (NASDAQ:HYPD) Financial Contrast